Gharbharan, 86 patient convalescent plasma late treatment RCT: 4% lower mortality [p=0.95] and 12% higher hospital discharge [p=0.68] https://c19p.org/gharbharan
copied to clipboard
Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection
et al., Nature Communications, doi:10.1038/s41467-021-23469-2
RCT 86 hospitalized patients, 43 treated with convalescent plasma, not showing significant differences with treatment. Authors conclude that the most likely explanation was already high antibody titers on the day of inclusion, and they recommend treating patients early. NCT04342182.
|
risk of death, 3.8% lower, RR 0.96, p = 0.95, treatment 6 of 43 (14.0%), control 11 of 43 (25.6%), NNT 8.6, adjusted per study, odds ratio converted to relative risk, multivariable logistic regression, primary outcome.
|
|
time to discharge, 11.7% lower, relative time 0.88, p = 0.68, treatment 43, control 43, adjusted per study, multivariable Fine and Gray regression.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Gharbharan et al., 5/27/2020, Randomized Controlled Trial, Netherlands, Europe, peer-reviewed, 32 authors, average treatment delay 10.0 days, trial NCT04342182.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.